Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23441842 | 0.65 | CDK9 (0.46) | CDK9CCNT1CNR2JAK2JAK1 | |
| SCHEMBL24463604 | 0.65 | KDM4E (0.55) | CDK9CCNT1GAAALDH1A1LMNA | |
| SCHEMBL24463365 | 0.63 | CCNT1 (0.65) | TYK2JAK3CDK9CCNT1JAK2 | |
| SCHEMBL9350636 | 0.58 | GRM1 (0.39) | JAK2JAK1GAAALOX15ALDH1A1 | |
| SCHEMBL3519853 | 0.58 | HCAR1 (0.42) | JAK3CDK9CCNT1JAK2JAK1 | |
| SCHEMBL9673866 | 0.57 | CCR5 (0.60) | CDK9CCNT1GAAALOX15ALDH1A1 | |
| SCHEMBL21663150 | 0.56 | ALDH1A1 (0.39) | CDK9CCNT1CLK1DYRK1ADYRK2 | |
| SCHEMBL23061550 | 0.55 | CYP1A2 (0.38) | ALDH1A1LMNA | |
| SCHEMBL17678354 | 0.55 | CYP11B2 (0.58) | CDK9CCNT1CLK1DYRK1ADYRK2 | |
| SCHEMBL23204987 | 0.54 | WDR5 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100562520-C | Imidazole derivatives iii | HOFFMANN LA ROCHE (CH) | 2009-11-25 | — | — | CN | disclosed |
| EP-1644351-B1 | Imidazole derivatives and their use in the treatment of mGluR5 receptor mediated disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| CN-1823054-A | Imidazole derivatives iii | HOFFMANN LA ROCHE (CH) | 2006-08-23 | — | — | CN | disclosed |
| US-7091222-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1644351-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003117-A1 | IMIDAZOLE DERIVATIVES III | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009878-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009878-A1 | Imidazole derivatives | GRIK5, GRM5, GRIK4 | TYK2 2383/4885JAK3 1811/4885CDK9 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.